Milestone Pharmaceuticals (NASDAQ:MIST) Given Buy Rating at HC Wainwright

Milestone Pharmaceuticals (NASDAQ:MIST)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They currently have a $25.00 target price on the stock.

Milestone Pharmaceuticals Stock Performance

Shares of Milestone Pharmaceuticals stock opened at $2.05 on Monday. The business has a fifty day simple moving average of $1.96 and a 200-day simple moving average of $1.66. The firm has a market cap of $109.33 million, a price-to-earnings ratio of -2.53 and a beta of 1.78. Milestone Pharmaceuticals has a fifty-two week low of $1.12 and a fifty-two week high of $2.75. The company has a quick ratio of 15.40, a current ratio of 15.40 and a debt-to-equity ratio of 2.18.

Milestone Pharmaceuticals (NASDAQ:MIST) last released its earnings results on Tuesday, November 12th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04. On average, equities analysts forecast that Milestone Pharmaceuticals will post -0.62 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Valeo Financial Advisors LLC grew its position in Milestone Pharmaceuticals by 100.0% during the 3rd quarter. Valeo Financial Advisors LLC now owns 20,000 shares of the company’s stock worth $30,000 after purchasing an additional 10,000 shares in the last quarter. Atria Investments Inc boosted its position in Milestone Pharmaceuticals by 44.4% during the 3rd quarter. Atria Investments Inc now owns 40,421 shares of the company’s stock worth $61,000 after acquiring an additional 12,430 shares during the period. BML Capital Management LLC grew its stake in Milestone Pharmaceuticals by 3.0% during the 3rd quarter. BML Capital Management LLC now owns 1,136,091 shares of the company’s stock valued at $1,727,000 after acquiring an additional 33,196 shares in the last quarter. Finally, PVG Asset Management Corp acquired a new position in shares of Milestone Pharmaceuticals in the 3rd quarter valued at about $46,000. 86.18% of the stock is owned by hedge funds and other institutional investors.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.